Global Transdermal Drug Delivery Market to 2020
Table of Contents
1.0 Executive Summary 17
1.1 Objectives of Report 17
1.2 Data Sources & Methodology 18
1.3 Key Findings & Observations 19
1.3.1 The Global Drug Delivery Market has a Growth Rate of 5% 19
1.3.2 The Transdermal Drug Delivery Market is Growing Vertically 20
1.3.3 Who are the Leading Players in the Market? 20
1.3.4 Neurodegenerative Disorders Such as Alzheimer’s and Parkinson’s Disease Will Propel the Future Market 21
1.3.5 Why is the Transdermal Drug Delivery Market so Promising? 21
1.3.6 What are the Main Drivers of the Market? 21
1.3.7 First, Second and Third Generation Drug Delivery Systems 22
1.3.8 The Niche Market of Commercially Available Skin Models 22
1.3.9 Transdermal Drug Delivery Technologies are Providing the Market with Niche Spaces 22
1.3.10 Nanotechnology is Transforming Transdermal Drug Delivery 23
1.3.11 Can Transdermal Drug Delivery be Applied to Cancer Vaccination? 23
1.3.12 Gene Therapy Advancement Using Transdermal Delivery 23
2.0 Transdermal Drug Delivery 24
2.1 Introduction 24
2.2 Developments of Transdermal Drug Delivery to Date 24
2.3 The Skin – Anatomy and Physiology 27
2.3.1 Drug Administration via the Intracellular Pathway 28
2.3.2 Drug Administration via the Intercellular Pathway 29
2.3.3 Fick’s Law 29
2.4 Factors that Influence Transdermal Drug Delivery 29
2.4.1 Parameters Influencing Skin Permeability 29
2.4.1.1 The Vehicle 29
2.4.1.2 Drug Concentration 30
2.4.1.3 Partition Coefficient 30
2.4.1.4 Variations in Skin Type 30
2.5 Strategies to Enhance Transdermal Drug Delivery 30
2.5.1 1st Generation Delivery Systems 30
2.5.2 2nd Generation Delivery Systems 31
2.5.2.1 Chemical Enhancers 31
2.5.2.2 Physical Enhancers 32
2.5.3 3rd Generation Delivery Systems 32
2.6 Comparison of Transdermal Delivery with Other Methods 34
2.7 Advantages of Transdermal Drug Delivery 35
2.7.1 First-Pass Metabolism 35
2.8 Disadvantages of Transdermal Delivery 36
2.9 Complications of Transdermal Therapy 36
2.9.1 Overdose 37
2.9.2 Skin Sensitivity and Reactions 37
2.9.3 MRI-Induced Skin Burns 38
3.0 Biomechanical & Pharmacological Elements Effecting Transdermal Drug Delivery 39
3.1 Factors That Influence Transdermal Drug Delivery 39
3.1.1 Rate of Permeation Across the Skin 39
3.1.2 Skin Characteristics 39
3.1.3 Drug Characteristics 39
3.1.4 pH and Pharmacokinetics 39
3.2 Transdermal Drug Design 40
3.2.1 Factors That Affect the Absorption of the Drug 40
3.2.1.1 Hydration and Temperature 40
3.2.1.2 Biotransformation of the Drug in the Skin 40
3.2.2 Selecting Drug and Vehicle 40
3.2.3 Drug Modification 40
3.2.3.1 Ion-Pair Formation 40
3.2.3.2 Pro-Drug 40
3.2.3.3 Drug Complexation 41
3.2.4 Thermodynamic Activity of the Drug within the Vehicle 41
3.2.4.1 Eutectic Systems 41
3.2.4.2 Vehicle Formulation 41
3.2.4.3 Modification of the Stratum Corneum 41
3.3 In Vitro Testing of Transdermal Drug Delivery Systems 41
3.3.1 Static Franz Diffusion Cell 42
3.3.2 Side-Bi-Side Cells 42
3.4 Commercially Available Skin Models for Transdermal Drug Testing 43
3.5 In vivo Testing of Transdermal Drug Delivery Systems 43
3.5.1 In vivo Testing of Drug Delivery Systems 44
3.5.2 Modelling of Transport Through the Skin 44
4.0 Transdermal Drug Delivery Technologies 46
4.1 Introduction 46
4.1.1 Local Application Formulations 46
4.1.2 Liquid Crystals for Transdermal Drug Delivery 46
4.1.3 Microemulsions for Transdermal Drug Delivery 47
4.1.4 Nanoemulsions for Transdermal Drug Delivery 49
4.1.5 Transdermal Gel Technology 50
4.1.6 Biphasix System 51
4.1.7 Penetration Enhancers 51
4.1.8 Chemical Enhancers 52
4.1.9 Nitric Oxide-Based Transdermal Drug Delivery 52
4.2 Vesicular Transdermal Carriers 52
4.2.1 Liposomes 53
4.2.2 Transfersomes 54
4.2.3 Ethosomes 55
4.2.4 Elastic Vesicles 55
4.3 Transdermal Patch 56
4.3.1 Types of Transdermal Patch 57
4.3.1a Single-layer Drug-in-Adhesive 57
4.3.1b Multi-layer Drug-in-Adhesive 58
4.3.1c Reservoir 58
4.3.1d Matrix Patch 58
4.3.1e Vapour Patch 59
4.3.2 Transdermal Patches Adhesives 59
4.3.3 h-Patch™ Controlled Release Micropump System 60
4.4 Patchless Transdermal Delivery System 60
4.5 Metered-Dose Transdermal System 60
4.6 Polymers for Transdermal Drug Delivery 61
4.6.1 Film Forming Polymeric Solutions 61
4.7 Physical Methods to Promote Transdermal Delivery 62
4.7.1 Electrotransport 62
4.7.2 Electroporation 62
4.7.2.1 Drug delivery by Electroporation 63
4.7.2.2 Electrochemotherapy 63
4.7.3 Cryoelectrophoresis 64
4.7.4 Iontophoresis 64
4.7.4.1 Application of Iontophoresis for Drug Delivery 64
4.7.4.2 Companies with Technologies for Drug Delivery by Iontophoresis 65
4.8 How Combining Electrophoresis and Iontophoresis Impacts Drug Delivery 66
4.9 Dermaportation 66
4.10 Radiofrequency-Driven Transdermal Delivery 67
4.11 Transcutaneous Drug Delivery by Electropulsation 67
4.11.1 Skin Patch Systems and Electrostatic Force 67
4.12 Heat-Aided Drug Delivery 67
4.13 Ultrasound 68
4.14 Magnetophoresis 69
4.15 Use of Lasers for Transdermal Drug Delivery 69
4.15.1 Laser-Induced Microporation 70
4.15.2 Painless Laser Injection 70
4.15.3 Laser-Induced Pressure Waves 70
4.15.3.1 Transdermal Drug Delivery by Laser-Assisted Changes in Skin 71
4.16 How Pressurized Gas is Transforming Transdermal Drug Delivery 72
4.17 Microscission Induced by Gas 72
4.18 Role of Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery 72
4.19 Microneedles and Dermal Microinjection 74
4.20 Microneedle Arrays for Drug Delivery 75
4.20.1 Microneedle Patch 75
4.20.2 Applications of Microneedles 75
4.20.3 AdminPatch® Microneedle Array 75
4.20.4 Dissolving Microneedles 76
4.21 Biodegradable Microneedles 76
4.22 Ceramic Microneedle Arrays 77
4.23 Dissolvable Microneedle Patches 77
4.23.1 MicorCor 78
4.23.2 MicroPyramid™ 78
4.24 Microstructured Transdermal Systems 78
4.25 Microneedle Transdermal Chip 79
4.26 Microneedle Applicator Device 80
4.27 DebioJect ™ Microneedle Technology 80
4.28 Silk Microneedles 81
4.29 Tattooing 82
4.30 ZP Patch Microprojections Technology 82
4.31 Other Microneedle Products Currently Available 83
4.32 Needlefree injections 83
4.33 Glide SDI® Solid Dose Injector 84
4.34 Jet Injection 84
4.34.1 Why is Needle-Free so Important? 85
4.34.2 Mini-Ject Needlefree Delivery System 85
4.34.3 PharmaJet Stratis 86
4.34.4 MicroJet for Painless Injections 86
4.34.5 Nanoliter-Volume Pulsed Microjets 86
4.35 SUMAVEL™ DosePro™ Needle-Less Injection 86
4.36 Skin Abrasion 87
5.0 How Nanotechnology is Transforming Transdermal Drug Delivery 88
5.1 Overview 88
5.2 Nanotechnology-Based Transdermal Drug Delivery 89
5.2.1 Nanobiotechnology for Transdermal Application 89
5.3 Nanoparticles and Nanoemulsions for Skin Disorders 90
5.4 Nanopatches 91
5.4.1 Vaxxas Nanopatch Technology 91
5.4.2 Effect of Mechanical Flexion on Penetration of Bucky Amino Acids Through the Skin 91
5.5 Inocyte™ Epidermal Drug Delivery System 91
5.6 Ionic Nanoparticle Technology 92
5.7 Solid Lipid Nanoparticles (SLN) Gels 93
5.8 siRNA- Nanoparticle Conjugates 93
5.9 Transdermal Nanoparticle Preparations for Systemic Effect 94
5.10 Micellar Nanoparticle Estradiol Emulsion (MNPEE) 94
5.11 Transferosomes 95
5.12 Nanocarriers 95
5.13 Nanotechnology for Vaccination and Immunotherapy 95
5.14 Safety Issues of Applications of Nanomaterial Carriers on the Skin 96
5.15 Comparison of Current Transdermal Drug Delivery Systems 96
6.0 Transdermal Drug Delivery and Disease States 98
6.1 Antiaging Products 98
6.2 Cancer 98
6.2.1 ?-Amino Levulinic Acid 98
6.2.2 Breast Cancer & Afimoxifene Gel 99
6.2.3 Cervical Cancer & Interferon ?2b 99
6.2.4 Prostate Cancer & Nitroglycerine 99
6.2.5 Prostate Cancer & Estradiol Gel 100
6.2.6 Prostate Cancer & Leuprolide Acetate 100
6.2.7 Skin Cancer & Caffeine 100
6.2.8 Cancer Vaccines 101
6.2.8.1 Intradermal Delivery Using Adenoviral Vectors 101
6.2.8.2 Peptide Cancer Vaccines 101
6.2.8.3 Electroporation of Anticancer Agents 102
6.3 Cardiovascular Disease 102
6.3.1 Transdermal Anticoagulants 102
6.3.2 Angina Pectoris 103
6.3.3 Atherosclerotic Cardiovascular Disease 103
6.3.3.1 Transdermal Oestrogen for Prevention of Atherosclerotic Cardiovascular Disease 103
6.3.4 Congestive Heart Failure 104
6.3.5 Hypertension 105
6.3.5.1 Clonidine 105
6.3.5.2 ?-Blockers 105
6.3.5.3 Calcium Channel Blockers 106
6.4 Chronic Fatigue Syndrome 109
6.5 Contraception 109
6.5.1 Female Contraception 109
6.5.1.1 Agile Therapeutics AG200-15 109
6.5.1.2 BAY86-5016 / FC Patch Low BAY86-5016 110
6.5.1.3 Desogestrel 110
6.5.1.4 Ortho Evra™ 111
6.5.2 Male Contraception 111
6.5.2.1 Transdermal Progestin Plus Testosterone 112
6.6 Diabetes 112
6.6.1 Insulin Drug Delivery 112
6.6.1.1 V-Go 112
6.6.1.2 GLP1 Agonist 113
6.7 Men’s Health 113
6.7.1 Benign Prostatic Hypertrophy 113
6.7.1.2 Tamsulosin Transdermal Drug Delivery System 114
6.7.2 Erectile Dysfunction 114
6.7.2.1 Topical and Transdermal Preparation for Erectile Dysfunction 115
6.7.3 Hypogonadism 115
6.7.3.1 Topical Testosterone 116
6.8 Musculoskeletal Disease 117
6.8.1 Osteoarthritis 117
6.8.2 Osteoporosis 117
6.8.2.1 Alendronate 118
6.8.2.2 Estrogen 118
6.8.2.3 Human Parathyroid Hormone 118
6.9 Nausea and Vomiting 119
6.9.1 Chemotherapy-Induced 119
6.9.2 Motion Sickness 119
6.9.3 Postoperative Vomiting 119
6.10 Neurological Disease 120
6.10.1 Alzheimer's Disease 120
6.10.1.1 Arecoline 120
6.10.1.2 Rivastigmine 120
6.10.1.3 Donepezil 120
6.11 Attention Deficit Hyperactivity Disorder 121
6.11.1 Methylphenidate 121
6.12 Bipolar Disorder 121
6.12.1 Lithium 121
6.13 Depression 122
6.13.1 Antidepressants 122
6.13.2 Selective Serotonin-Reuptake Inhibitors 122
6.13.3 Fluoxetine 123
6.13.4 Monoamine Oxidase Inhibitors 123
6.13.5 Selegiline 123
6.13.6 Trazodone Hydrochloride 124
6.13.7 Venlafaxine 124
6.13.8 Bupropion 124
6.14 Epilepsy 124
6.15 Migraine 125
6.15.1 Sumatriptan 125
6.15.2 Zolmitriptan 126
6.16 Parkinson's Disease 126
6.16.1 Introduction 126
6.16.2 Dopamine Agonists 126
6.16.2.1 Levodopa 127
6.16.2.2 Rotigotine 127
6.16.3 Other Agents 128
6.17 Restless Leg Syndrome 128
6.17.1 Rotigotine 128
6.18 Schizophrenia 128
6.18.1 Haloperidol 129
6.18.2 Risperidone 129
6.18.3 Blonanserin 129
6.19 Tinnitus/Vertigo 130
6.20 Tourette syndrome 131
6.20.1 Nicotine 131
6.21 Multiple Sclerosis 131
6.22 Respiratory Diseases 131
6.22.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD) 131
6.23 Skin disorders 132
6.23.1 Cutaneous Leishmaniasis 132
6.23.2 Hair Loss 132
6.23.3 Iontophoretic Drug Delivery for Nail Disorders 133
6.23.4 Psoriasis 133
6.23.4.1 Nanoemulsions for Paxitacel in Psoriasis 133
6.23.4.2 Iontophoresis for Treatment of Psoriasis 134
6.24 Overactive Bladder and Urinary Incontinence 134
6.24.1 Oxybutynin 134
6.25 Pain 134
6.25.1 Chronic Pain 134
6.25.2 Transdermal Local Anesthetics 135
6.25.3 Transdermal Fentanyl for the Management of Postoperative Pain 136
6.25.4 Fibromyalgia 136
6.25.5 Minor Medical Procedures 137
6.25.6 Neuralgia 137
6.25.6.1 Lidoderm 137
6.25.7 Nonsteroidal Anti-Inflammatory Drugs 137
6.25.7.1 Topical NSAIDs 137
6.25.8 Ketoprofen 138
6.25.9 Opioids 138
6.25.10 Cancer Pain 139
6.25.10.1 Fentanyl 139
6.25.10.2 Nitroglycerine 139
6.25.10.3 Buprenorphine 140
6.26 Smoking Cessation 140
6.26.1 Nicotine Replacement Therapy 140
6.26.2 Nicotine Patch in Pregnancy 140
6.27 Viral infections 142
6.27.1 Transdermal Nanoparticles for Immune Enhancement in HIV 142
6.28 Women's Health 143
6.28.1 Dysmenorrhea 143
6.28.2 Female Infertility 143
6.28.3 Female Sexual Arousal Disorder 144
6.28.4 Menopause 145
6.28.4.1 Hormone Replacement Therapy 145
6.28.4.2 Estradiol 145
6.28.4.3 Parathyroid Hormone for Postmenopausal Osteoporosis 146
6.28.4.4 Testosterone and Low Libido 146
6.29 Transdermal Nutraceuticals 147
7.0 Gene Therapy and Transdermal Drug Delivery 148
7.1 Overview 148
7.2 Plasmid DNA and Electroporation 148
7.2.1 TriGrid™ Delivery System 149
7.2.2 CELLECTRA® 149
7.2.3 Magnetic Pulse Electroporation 150
7.3 Antisense Therapy 150
8.0 Vaccines and Transdermal Drug Technology 152
8.1 Introduction 152
8.1.1 The Skin as an Immune Organ 152
8.1.1.1 Langerhans Cells- Epidermal Antigen Presenting Cells 152
8.1.1.2 Keratinocytes- Immune Competent Epithelial cells 152
8.1.1.3 Dendritic Epidermal T Cells (DETC) ?? T cells -Specialised Resident Epithelial Cells 152
8.1.1.4 Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis 153
8.1.1.5 Melanocytes-Epidermal Pigment Cells With Immune Properties 153
8.2 Current Technologies 153
8.2.1 Dissolvable Microneedle Array 153
8.2.2 Electroporation for Administering DNA Vaccines 154
8.2.3 Microneedles for Transdermal Vaccine Delivery 154
8.2.4 Needle-Free Delivery of Vaccines 155
8.3 Applications for Transdermal Vaccination 156
8.3.1 HIV/AIDS Vaccine 156
8.3.2 Transdermal DNA Influenza Vaccine 157
8.3.3 Transdermal A? Vaccine for Alzheimer’s Disease 157
8.3.4 Transdermal Vaccine for Traveller’s Diarrhoea 157
9.0 Global Drug Delivery Market 158
9.1 Overview and Analysis 158
9.2 USA Drug Delivery Market 160
9.3 European Drug Delivery Market 162
9.4 Emerging Drug Delivery Markets 164
9.5 The Advanced Drug Delivery Landscape 164
9.6 Transdermal Drug Delivery Market 166
9.7 Smoking Cessation Drug Market 169
9.7.1 Nicotine Replacement Therapeutics 171
9.7.2 Non-Nicotine Containing Therapeutics 171
9.7.3 Smoking Cessation Products in the Pipeline 171
9.8 Neurodegenerative Disorders Such as Alzheimer’s & Parkinson’s disease will Propel the Future Market 172
9.9 How Transdermal Systems Relate to the Global Pain Market 172
9.9.1 Neuropathic Pain Market (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020 173
9.9.2 Transdermal Products Within the Neuropathic Pain Market 176
9.10 How Transdermal Systems Relate Within the Generic Market 176
9.11 Duragesic and Generic Fentanyl Transdermal System Competition 179
9.12 Lidocaine Market Analysis 181
9.13 Who are the Leading Players in the Market? 182
9.14 What is Driving the Transdermal Drug Delivery Market? 184
9.15 Increased Number of Geriatric and Pediatric Patients is Propelling the Market 184
9.16 Unmet Needs Within the Transdermal Drug Delivery Market 185
9.17 Women’s Health Market 185
10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation 187
10.1 Actavis 187
10.2 Actelion 188
10.3 GlaxoSmithKline 189
10.4 Bayer 190
10.5 Mylan Pharmaceuticals 191
10.6 Novartis 191
10.7 Upsher-Smith 193
10.8 Ascend Therapeutics 195
10.9 AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp) 195
10.10 Janssen Pharmaceuticals 195
10.11 Lavipharm 196
10.12 Noven Pharmaceuticals 197
10.13 ProStrakan 198
10.14 Shire 198
10.15 Hercon Pharmaceutical 199
10.16 Kremers Urban Pharmaceuticals 199
10.17 Nitto Denko 199
10.18 Teva Pharmaceutical Industries 199
10.19 Endo International 201
10.20 Teikoku USA 201
10.21 Boehringer Ingelheim 201
10.22 3M 203
10.23 UCB 204
10.24 ParPharm 204
11.0 Transdermal Drug Delivery Company Financial Analysis 208
11.1 Actavis 210
11.2 Actelion 212
11.3 GlaxoSmithKline 217
11.3.1 ViiV Healthcare 218
11.4 Bayer 218
11.5 Mylan Pharmaceuticals 224
11.6 Novartis 228
11.7 Janssen Pharmaceuticals (Johnson & Johnson) 232
11.8 Shire 236
11.9 Nitto Dento 237
11.10 Teva Pharmaceuticals 238
11.11 Endo International 243
11.12 Boehringer Ingelheim 246
11.13 3M 248
11.14 UCB 250
11.15 ParPharm 253
12.0 Current Transdermal Drug Delivery Products on the Market 255
12.1 Actavis 255
12.1.1 Androderm 255
12.1.2 Fentanyl Transdermal System 255
12.1.3 Lidocaine Topical Patch 255
12.1.4 Oxytrol 255
12.2 Actelion 256
12.2.1 Vachlor Gel (mechlorethamine) 256
12.3 GlaxoSmithKline 256
12.3.1 Niquitin/Nicoderm 257
12.4 Bayer 257
12.5 Mylan Pharmaceuticals 258
12.5.1 Clonidine Transdermal System 258
12.5.2 EMSAM (Selegiline Transdermal System) 258
12.5.3 Estradiol Transdermal System 258
12.5.4 Fentanyl Transdermal System 259
12.5.5 Nitroglycerin Transdermal System 259
12.5.6 XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System) 259
12.6 Novartis 259
12.6.1 Exelon Patch (Rivastigmine Transdermal System) 261
12.6.2 Duragesic - Fentanyl Patches 261
12.6.3 Transderm Scop - Scopolamine Patches 262
12.7 Upsher-Smith 262
12.7.1 Vogelxo – Testosterone (1%) Gel 262
12.8 ASCEND Therapeutics 262
12.8.1 EstroGel® 262
12.9 AMAG Pharmaceuticals (Lumara Health) 262
12.9.1 Evamist® 262
12.10 Janssen Pharmaceuticals 262
12.10.1 OrthoEvra® 263
12.10.2 Duragesic® 263
12.11 Lavipharm 263
12.11.1 Fentadur 264
12.11.2 Nicotine Transdermal Patch 264
12.11.3 Acne Transdermal Patch 264
12.11.4 Trinipatch 264
12.12 Noven Pharmaceuticals 264
12.12.1 Minivelle® 264
12.12.2 CombiPatch® 264
12.12.3 Daytrana® 265
12.13 ProStraken 265
12.13.1 Sancuso® 265
12.14 Shire 265
12.14.1 Daytrana® CII 265
12.15 Hercon Pharmaceuticals 265
12.15.1 Nitroglycerin Transdermal System 265
12.16 Kremers Urban Pharmaceuticals 265
12.16.1 Nitroglycerin Transdermal System 265
12.17 Nitto Dento 265
12.17.1 Bisono Tape 265
12.17.2 Penles Tape 265
12.17.3 Passport Advanced Drug Delivery System 265
12.18 Teva Pharmaceuticals 266
12.18.1 Zecuity 266
12.18.2 Transdermal Fentanyl (generic) 266
12.18.3 Tev Tropin 266
12.19 Endo International 267
12.19.1 Lidoderm®Patch 267
12.19.2 Fortesa Gel 267
12.20 Teikoku 267
12.20.1 Lidoderm® 1 267
12.20.2 IontoPatch® 268
12.21 3M 268
12.21.1 3M Fentanyl Transdermal Delivery System 268
12.21.2 3M Rivastigmine Transdermal Delivery System 268
12.21.3 Microneedles 269
12.22 UCB 269
12.22.1 Neupro® 269
12.23 ParPharm 269
12.23.1 Fentanyl Transdermal System 269
13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market 270
13.1 Drivers of the Market 270
13.1.1 Will Patent Expirations and Introduction of Generics Drive the Short Term Transdermal Market? 270
13.1.2 Increased Patient Compliance Rates 270
13.1.3 Increased Incidence of Chronic Conditions & Application of Patch Technology to These Areas 271
13.1.3.1 Cancer 271
13.1.3.2 Cardiovascular Disease 273
13.1.3.3 Diabetes 273
13.1.3.4 Men’s Health 273
13.1.3.5 Neurological Disease 273
13.1.4 Increased Geriatric and Pediatric Drug Administration Requirements 274
13.2 Restraints and Weaknesses of the Transdermal Drug Delivery Market 274
13.2.1 Technical Restraints 274
13.2.2 Drug Adverse Reactions 275
13.2.3 Drug Failures 275
13.3 Opportunities Within the Market Place 275
13.3.1 High Number of Pharmaco & Drug Delivery Company Collaboration 276
13.3.4 Targeted Transdermal Drug Delivery 277
13.4 Challenges and Barriers to Market Entry 277
Appendix 1: Further Reading & Bibliography 279
List of Tables
Table 2.1 Currently Approved Transdermal Drug Delivery Systems by Indication & Type 21
Table 2.2: Transdermal Products for Local Tissue Treatment Currently on the US Market 22
Table 2.3 Chemical Enhancers for Transdermal Delivery Systems 22
Table 2.4: Third Generation Drug Delivery Systems, Mechanism, Commercial Names, Company Name and Active Ingredient 32
Table 2.5: Advantages of Transdermal Drug Delivery 35
Table 2.6 Skin Irritation and Sensitization Associated with Transdermal Delivery Systems 36
Table 3.1 Commercially Available Skin Models for Transdermal Drug Testing 43
Table 3.2: Methods to Assess Drug Penetration into and/or Across the Skin 44
Table 4.1: Advantages and Disadvantages of Micro-Emulsions 47
Table 4.2: Comparison of Microemulsion with Conventional Emulsion 48
Table 4.3 Overview of Transdermal Drug Delivery Systems Containing Microemulsions 48
Table 4.4. Commercial Nanoemulsion Formulation 50
Table 4.5 Advantages and Disadvantages of using Nanoemulsions for Transdermal Drug Delivery 50
Table 4.6 Transdermal Gel Types 50
Table 4.7 Advantages and Disadvantages of Transdermal Gels 50
Table 4.8 Enhancer Mechanisms of Action 52
Table 4.9 Typical Transfersome Composition 54
Table 4.10 Use of Transferosomes in Transdermal Drug Delivery 54
Table 4.11 Use of Ethosomes in Transdermal Drug Delivery 55
Table 4.12 Research Studies using Invasomes 56
Table 4.13 Other Elastic Vesicles as drug carriers 56
Table 4.14 Pressure Sensitive Adhesives 59
Table 4.15 Properties of Pressure Sensitive Adhesives 60
Table 4.16 Patchless Transdermal Drugs 60
Table 4.17 Use of Polymers in Transdermal Drug Delivery Systems 61
Table 4.18 Topical Delivery of Drugs and Macromolecules Into the Skin Using Electroporation 63
Table 4.19 Clinical Trial Data of Patient outcomes using Electrochemotherapy 63
Table 4.20 Factors that Affect the Efficacy of Iontophoresis 64
Table 4.21 Applications of Transdermal Iontophoretic Drug Delivery 65
Table 4.22 Iontophoretic Devices on the Market 65
Table 4.23 Iontophoretic Products in Development 65
Table 4.24 Drug Delivery via Radiofrequency-Driven Transdermal Delivery 67
Table 4.25 Ways in Which Ultrasound can Enhance Drug Delivery 68
Table 4.26 Types of Microneedles 74
Table 4.27 Properties of Microneedles 74
Table 4.28 Applications of Microneedles 75
Table 4.29 Comparison of Solid and Hollow Microstructured Transdermal Systems 79
Table 4.30 Advantages and Disadvantages of Needlefree Injections 84
Table 4.31 Needlefree Injectors on the Market 85
Table 5.1 Nanocarriers Frequently used in Transdermal Drug Delivery Systems 88
Table 5.2 Applications of Nanocarriers in Transdermal Drug Delivery 88
Table 5.3 Summary of the Nanocarrier Applications in Transdermal Drug Delivery 89
Table 5.4 Nanoparticles and Nanoemulsions for Skin Disorders 90
Table 5.5 Potential Uses of Solid Lipid Nanoparticles (SLN) Formulations 93
Table 5.6 Nanotechnology-Based Transdermal Vaccination and Immunotherapy 95
Table 6.1Transdermal Anti-Aging Products 98
Table 6.2: Cardiovascular Disease Subtypes 102
Table 6.3 Commercially Available Nitroglycerine Patches 103
Table 6.4. Potential Transdermal Treatments for Congestive Heart Failure 104
Table 6.5 Transdermal Drug Delivery Systems for Antihypertensive Drugs 105
Table 6.6 Research Advances in Systemic Delivery of ?-blockers via Skin 106
Table 6.7: Calcium Channel Blockers with High Potential for use in Transdermal Delivery 107
Table 6.8 Research Advances in Systemic Delivery of Calcium Channel Blockers via Skin 107
Table 6.9 Agile Therapeutics Pipeline Transdermal Contraceptives 109
Table 6.10: Main Treatment Profiles of Benign Prostate Hypertrophy 114
Table 6.11 Advantages of Tamsulosin Transdermal Drug Delivery System 114
Table 6.12 Treatments for Erectile Dysfunction 114
Table 6.13 Hypogonadism Primary-Originating from a Problem in the Testicles 115
Table 6.14 Hypogonadism Secondary-Problem with the Pituitary or Hypothalamus-Testicles are Normal 115
Table 6.15 Commercially Available Topical Testosterone Formulations 116
Table 6.16 Osteoporosis Risk Factors 117
Table 6.17 Hormone and Bisphosphonate Therapy to Treat Osteoarthritis 117
Table 6.18 Research Findings on Transdermal Administration of Alendronate 118
Table 6.19 Major Types and Causes of Epilepsy 125
Table 6.20: NeuroDerm’s Levodopa/Carbidopa Candidate Product Portfolio for Parkinson’s Disease 127
Table 6.21 Potential Transdermal Drug Treatments for Pain 134
Table 6.22 Local Topical Anesthetics by Generic Name and Pharmaokinetic Profiles 135
Table 6.23 Possible Transdermal Therapies in the Treatment of Fibromyalgia 136
Table 6.24 Commercially Available Topical Anaesthetics 137
Table 6.25 Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) 138
Table 6.26 Transdermal Opioids in Current Research 138
Table 6.27 Transdermal Duragesic Patch Doses Available 139
Table 6.28 Non-Transdermal Methods for Nicotine Replacement 141
Table 6.29 Non-nicotine Replacement and Anti-Smoking Treatments with Potential for Transdermal Drug Delivery 141
Table 6.30 Common Causes of Female Infertility 143
Table 6.31 Transdermal Therapies Currently Under Development for the Treatment of Female Sexual Arousal Disorder 144
Table 7.1 Modification of the Nucleic Acid Strand for more Effective Transdermal Delivery 151
Table 7.2: Transdermal Delivery Methods of Antisense in Research 151
Table 8.1 Advantages and Disadvantages of Dissolvable Microneedles 153
Table 8.2 Vaccines and Model Antigens used in Microneedle-based Vaccine Delivery Trials 155
Table 9.1: Main Sub-Markets of the Global Drug Delivery Market 158
Table 9.2: Global Drug Delivery System Historical Market ($ Billions) and CAGR 2010-2014 158
Table 9.3: Global Drug Delivery System Market Forecast ($ Billions) and CAGR 2014-2020 159
Table 9.4: Factors Providing Momentum to The US Drug Delivery Market 161
Table 9.5: USA Drug Delivery System Market Historical Figures 2010-2014 161
Table 9.6: USA Drug Delivery System Market Forecast 2014-2020 161
Table 9.7: Europe Drug Delivery Market Historic Worth 2010-2014 162
Table 9.8: Europe Drug Delivery Market Forecast 2014-2020 163
Table 9.9: Main Pharmaco Players in Europe 164
Table 9.10: Factors Propelling the Asian Drug Delivery Market 164
Table 9.11: Top Selling Indications for Transdermal Delivery Patch Systems 168
Table 9.12: Top Indications and Active Ingredients Used Within the Transdermal Drug Delivery Market 168
Table 9.13: Top Seven Transdermal Drug Products By Sales 169
Table 9.14: Market Changing Smoking Cessation Products in Development Stage 171
Table 9.15: Top Ten Most-Prescribed Drugs in the U.S., 2011 173
Table 9.16: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2010-2014 174
Table 9.17: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020 175
Table 9.18: Current Top Therapeutics within the Neuropathic Pain Market 175
Table 9.19: Global Generics Market Value 2012-2018 177
Table 9.20: Top Ten Generic Manufacturer Companies 178
Table 9.21: Vulnerable Branded Transdermal Patch Systems Once Patent Protection Expires 179
Table 9.22: Main Competitors in the Duragesic Generic Fentanyl Transdermal System Market 180
Table 9.23: Key Players in the Transdermal Drug Delivery Market 184
Table 9.24: Factors Driving the Transdermal Drug Delivery Market 184
Table 9.25: Top Women’s Health Brands by USA Sales 186
Table 10.1 Actavis Structure 187
Table 10.2 Actavis Key Facts and Figures 187
Table 10.3 Business Acquisitions 187
Table 10.4 Actavis Business Development Profile 187
Table 10.5 Recent Actavis Disposals 188
Table 10.6 Actelion Pulmonary Arterial Hypertension Franchise 188
Table 10.7: Actelion Speciality Transdermal/Oral Products 189
Table 10.8: Actelion Therapeutic Pipeline Products 189
Table 10.9: GlaxoSmithKline Overview 2013 189
Table 10.10: GlaxoSmithKline Objectives and Strategic Business Plan 189
Table 10.11:Bayer Therapeutic Areas of Interest 190
Table 10.12: Bayer Important Drug Candidates Currently Submitted for Approval 190
Table 10.13: Bayer Important Agents in R&D Development Stages and Clinical Phases 190
Table 10.14: Therapeutic Portfolio of Mylan Pharmaceuticals 191
Table 10.15: Top Transdermal drug Delivery Products: Novartis 193
Table 10.16: Upsher-Smith Therapeutic Areas of Interest 194
Table 10.17: Upsher-Smith Key Branded Products (Women’s Health, Generics, Consumer) 194
Table 10.18: Upsher-Smith Key Generic Products 194
Table 10.19: Lumara Health’s Product Portfolio 195
Table 10.20: Janssen Pharmaceuticals Therapeutic Areas of Interest 195
Table 10.21: Johnson & Johnson Pharmaceutical Division Therapeutic Areas of Interest 196
Table 10.22: Lavipharm Pharmaceutical Division Therapeutic Areas of Interest 196
Table 10.23: Lavipharm Over The Counter Division Therapeutic Areas of Interest 197
Table 10.24: Lavipharm Manufacturing Capacity of Pharmaceutical Products 197
Table 10.25: Noven Pharmaceuticals Timeline Events 197
Table 10.26: Noven Pharmaceuticals Current and In-Development Product Portfolio 198
Table 10.27 Nitto Denko Business Field and Major Products 199
Table 10.28 Teva Pharmaceuticals Business Highlights 199
Table 10.29 Teva Pharmaceuticals Key Strengths 200
Table 10.30 Teva Business Strategies 200
Table 10.31: Teva Pharmaceuticals Generics Business Facts 200
Table 10.32 Teva Pharmaceuticals Bestselling APIs 200
Table 10.33 Endo International Milestones 201
Table 10.34 Endo International Competitive Strengths 201
Table 10.35 Endo International Business Segments 201
Table 10.36 Endo International Acquisitions During FY2013 201
Table 10.37 Boehringer Business Segments and Therapeutic Areas of Interest 202
Table 10.38: Boehringer Ingelheim Branded Prescription Medicine Product Portfolio 202
Table 10.39: Boehringer Ingelheim Animal Health Care Product Portfolio 202
Table 10.40: Boehringer Ingelheim Consumer Health Care Product Portfolio 203
Table 10.41 3M Business Segments 203
Table 10.42: UCB Recent Partnerships 204
Table 10.43 Par Pharmaceutical Key Information 205
Table 10.44 Par Pharmaceutical Generic Product Portfolio 205
Table 10.45 Strativa Key Information 206
Table 10.46 Strativa Product Portfolio 206
Table 10.47 ParPharma Sterile Product Key Data 207
Table 10.48 ParPharma Sterile Product Portfolio 207
Table 11.1 Actavis Financial Highlights (Millions) 209
Table 11.2 Actavis Speciality Brands Pipeline Products 210
Table 11.3: Actelion Core Performance Figures FY2012-FY2013 211
Table 11.4: Actelion Employee Number by Department 212
Table 11.5: Actelion Product Portfolio by Therapeutic Area 212
Table 11.6: GlaxoSmithKline Financial Review FY2013 212
Table 11.7: GlaxoSmithKline Pharmaceuticals Sales by Therapeutic Area FY2013 214
Table 11.8: GlaxoSmithKline Vaccine Sales by Therapeutic Area FY2013 214
Table 11.9: GlaxoSmithKline Pharmaceuticals & Vaccines Sales Facts by Region FY2013 214
Table 11.10: GlaxoSmithKline Consumer Healthcare Sales by Therapeutic Area FY2013 215
Table 11.11: GlaxoSmithKline Pharmaceutical & Vaccine Turnover by Geographic Area FY2013 215
Table 11.12 GlaxoSmithKline Core R&D Expenditure FY2013 215
Table 11.13: GlaxoSmithKline Late Stage Pipeline Products 216
Table 11.14: ViiV Healthcare Top Therapeutic Agents FY2013 218
Table 11.15: Bayer Top Therapeutic Agents with High Potential FY2013 219
Table 11.16: Bayer Sales by Geographical Region FY2012-FY2013 221
Table 11.17: Bayer Top Pharmaceutical Products by Global Sales, FY2012-FY2013 222
Table 11.18: Bayer R&D Expenditure by Geographical Region FY2012-FY2013 223
Table 11.19: Top Selling Novartis Products FY2013 Globally 230
Table 11.20: Top Twenty Novartis Products FY2013 (by Sales) Globally 230
Table 11.21: Johnson & Johnson Top Performing Pharmaceutical Therapeutics FY2013 233
Table 11.22: Johnson & Johnson Top Performing New Pharmaceutical Therapeutics FY2013 233
Table 11.23: Nitto Dento Financial Highlights FY2013 237
Table 11.24: Teva Pharmaceuticals Financial Figures FY2010-FY2013 239
Table 11.25 Teva Pharmaceuticals Generic Medicine Revenues 240
Table 11.26: Teva Pharmaceuticals Generic Medicines Launched in 2013 240
Table 11.27 Teva Pharmaceuticals Specialty Medicines Revenue Breakdown (US$ Millions) 2011-2013 241
Table 11.28 Teva Pharmaceuticals Comparison of Specialty Product Sales FY2012 & 2011 241
Table 11.29: Teva Pharmaceuticals Selected Speciality Product Pipeline in Clinical Development 241
Table 11.30: Teva Pharmaceuticals New Therapeutic Entity (NTE) Products 242
Table 11.31: Teva Pharmaceuticals Revenues from Over the Counter (OTC) Products 242
Table 11.32 Endo International Top Selling Products per Business Segment 243
Table 11.33 Endo International Select Products From Qualitest Pharmaceuticals Portfolio 245
Table 11.34 Endo International Select Products From AMS Portfolio 245
Table 11.35: Boehringer Ingelheim Top Prescription Medicines FY2013 247
Table 11.36: Boehringer Ingelheim Top Consumer Health Products FY2013 247
Table 11.37: Boehringer Ingelheim R&D Highlights FY2013 247
Table 11.38: Boehringer Ingelheim Clinical Studies FY2013 248
Table 11.39: Boehringer Ingelheim R&D Animal Health 248
Table 11.40: 3M Sales Growth by Business Segment FY2013 249
Table 11.41: 3M Sales and Operating Income Detail by Business Segment FY2012-FY2013 249
Table 11.42: UCB Business Performance Highlights FY2013 251
Table 11.43: UCB North American Market Sales – Key Business Facts FY2013 251
Table 11.44: UCB European Market Sales – Key Business Facts FY2013 252
Table 11.45: UCB Japanese Market Sales – Key Business Facts FY2013 252
Table 11.46: UCB Emerging Market Sales – Key Business Facts FY2013 252
Table 11.47: UCB Research & Development Milestones 253
Table 11.48: UCB Product Pipeline 253
Table 12.1 Actavis Transdermal Delivery System Product Portfolio 255
Table 12.2: Actavis Pharma Product Portfolio 256
Table 12.3: GlaxoSmithKline Consumer Healthcare Products 256
Table 12.4: GlaxoSmithKline Niquitin/Nicoderm Transdermal Patch 257
Table 12.4: Bayer’s Product Portfolio by Therapeutic Area 257
Table 12.5: Bayer Women’s Healthcare Product Portfolio 258
Table 12.6: Top Global Cancer Therapeutics and Mechanism of Action– Novartis Portfolio 259
Table 12.7: Top Global Primary Care Therapeutics and Mechanism of Action– Novartis Portfolio 259
Table 12.8: Top Global Established Care Therapeutics and Mechanism of Action– Novartis Portfolio 260
Table 12.9: Top Global Specialty Care Therapeutics and Mechanism of Action– Novartis Portfolio 260
Table 12.10: Top Global Integrated Hospital Care Therapeutics and Mechanism of Action–Novartis Portfolio 260
Table 12.11: Top Transdermal drug Delivery Products: Novartis 261
Table 12.12: Janssen Pharmaceuticals Full List of Therapeutic Products 262
Table 12.13: Noven Pharmaceuticals Transdermal Drug Delivery Product Portfolio 264
Table 12.14: Teva Pharmaceuticals Speciality Products 266
Table 12.15: Endo International Product Portfolio 267
Table 12.16: Teikoku Transdermal Product Portfolio 268
Table 12.17: 3M Drug Delivery System Product Portfolio 268
Table 12.18: UCB NeuPro Transdermal Patch Details 269
Table 12.19: UCB’s Neupro Timeline 2006-2013 269
Table 13.1: Technical Transdermal Product Challenges 278
Table 13.2: Technical Challenges of Generic Transdermals 278
Table 13.3: Technical Transdermal Product Development Challenges 278
List of Figures
Figure 2.1 Anatomy of the Stratum Corneum 27
Figure 2.2 Intracellular Pathways Through the Stratum Corneum 28
Figure 2.3 Fick’s Law of Diffusion 29
Figure 2.4 Transdermal Iontophoresis Delivery Pathway: A Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine 32
Figure 3.1 Static Franz Diffusion Cell 42
Figure 3.2: Side-Bi-Side Cells 43
Figure 4.1 Different forms of Microemulsion 47
Figure 4.2 Multi-Compartmental Biphasix™ System 51
Figure 4.3 Possible Mechanisms of Action of Liposomes as Skin Drug Delivery Systems 53
Figure 4.4 Transdermal Patch Composition 57
Figure 4.5: Single-Layer Drug-in-Adhesive Transdermal Patch 57
Figure 4.6: Multi-Layer Drug-in-Adhesive Transdermal Patch 58
Figure 4.7 Reservoir Transdermal Drug Delivery Patch 58
Figure 4.8 Matrix Transdermal Drug Delivery Patch 59
Figure 4.9 The Metered Dose Transdermal System 61
Figure 4.10 Laser Ablation of Skin for Transdermal Drug Delivery 71
Figure 4.11 Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery 73
Figure 4.12 Solid, Coated, Dissolving and Hollow Microneedles 74
Figure 4.13 AdminPatch Microneedle Array 76
Figure 4.14 MicroCor Microneedle Array 78
Figure 4.15 Microstructured Transdermal Systems 79
Figure 4.16 Zosanos Reusable Microflux Transdermal Microprojection Delivery System 80
Figure 4.17 DebioJect Microneedle Device 81
Figure 4.18 Transdermal Drug Delivery System by ZP Patch Technology 83
Figure 4.19 Injection vs Jet Injection 85
Figure 5.1 InoCyte Microinjectors 92
Figure 6.1 Agile Therapeutic Twirla Patch 110
Figure 6.2 The Endocrinology of Spermatogenesis and Male Hormonal Contraception 111
Figure 6.3 V-Go Insulin Delivery Device 113
Figure 6.4 Selective Serotonin-Reuptake Inhibitor (SSRI) Mode of Action 122
Figure 6.5 Ionsys Patch by ALZA Corp 136
Figure 6.6 DermaVir Transdermal Immunisation 142
Figure 7.1 Viral Gene Therapy Using an Adenovirus Vector 148
Figure 7.2 Preventing Protein Translation Using Antisense 150
Figure 8.1 Delivery of DNA Vaccine with in vivo Electroporation Enhances Cellular Immune Responses 154
Figure 8.2 Devices for Plasmid DNA Delivery 156
Figure 9.1: Global Drug Delivery System Historical Market ($ Billions) and CAGR 2010-2014 159
Figure 9.2: Global Drug Delivery System Market Forecast ($ Billions) and CAGR 2014-2020 159
Figure 9.3: Geographical Breakdown of Global Drug Delivery Market – USA, Europe, Asia, RoW 2014 160
Figure 9.4: Geographical Breakdown of Global Drug Delivery Market – USA, Europe, Asia, RoW 2017 160
Figure 9.5: USA Drug Delivery System Market Historical Figures 2010-2014 161
Figure 9.6: USA Drug Delivery System Market Forecast 2014-2020 162
Figure 9.7: Europe Drug Delivery Market Historic Worth 2010-2014 163
Figure 9.8: Europe Drug Delivery Market Forecast 2014-2020 163
Figure 9.9: The Advanced Global Drug Delivery – (Transdermal, Targeted, Transmucosal, Prodrugs, Sustained-Release, Intra-Uterine Device & Implant) Landscape 2007-2014 165
Figure 9.10: The Global Transdermal Drug Delivery Market 2010-2014 167
Figure 9.11: The Global Transdermal Drug Delivery Market 2014-2018 167
Figure 9.12: Transdermal Drugs (Number) in Pre-Clinical and Clinical Trials, Discontinued/Suspended and on the Global Market 168
Figure 9.13: Top Seven Transdermal Drug Products By Sales 168
Figure 9.14: Number of Premature Death Caused by Smoking Tobacco 2014-2030 169
Figure 9.15: Market Share of Smoking Cessation Therapeutics 2011-2016 169
Figure 9.16: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2010-2014 174
Figure 9.17: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020 175
Figure 9.18: Leading Therapeutics by Sales within the Neuropathic Pain Market 2014-2020 176
Figure 9.19: Global Generics Market Value 2012-2018 177
Figure 9.20: Number of US Patent Expirations by Oral and Differentiated Generics 2011-2019 179
Figure 9.21: Duragesic (Fentanyl Transdermal System) Sales 2002-2012 180
Figure 9.22: Comparison of Duragesic Sales to Mylan and Actavis Fentanyl Generic Transdermal 181
Figure 9.23: Endo Health Solutions – Lidoderm Net Sales 2011-2013 182
Figure 9.24: Endo Pharma Solutions Lidocaine Percentage of Total Business Revenue 2011-2014 182
Figure 9.25: Women’s Health Market Worth 2014-2018 186
Figure 10.1: Business Units of Novartis 192
Figure 11.1: Actavis Sales By Geographic Region, FY2013 209
Figure 11.2: Actavis Sales by Therapeutic Area FY2013 209
Figure 11.3: Actavis Sales by Specialty Segment FY2012 210
Figure 11.4 Actelion Sales by FY2011-FY2013 211
Figure 11.5 Actelion Core Earnings FY2011-FY2013 211
Figure 11.6 Actelion Core R&D Expenditure 2011-2013 212
Figure 11.7 GSK Turnover by Business FY2013 213
Figure 11.8 GSK Turnover by Region FY2013 213
Figure 11.9 GSK Turnover by Segment FY2013 214
Figure 11.10 GlaxoSmithKline Pharmaceutical Research & Development Investment FY2013 216
Figure 11.11: Bayer Revenue Generated From Sales FY2012-FY2013 219
Figure 11.12: Bayer Net Income FY2012-FY2013 219
Figure 11.13: Bayer Earnings Before Financial Result and Taxes FY2012-FY2013 220
Figure 11.14: Bayer Revenue Generated From Health Care, Crop Care and Material Science Divisions, FY2012-FY2013 220
Figure 11.15: Bayer Percentage Sales by Business Division FY2013 221
Figure 11.16: Bayer Sales by Geographical Region FY2012-FY2013 221
Figure 11.17: Bayer Top Five Pharmaceutical Drug Revenue Generators FY2013 222
Figure 11.18: Bayer Research and Development Expenditure FY2012-FY2013 223
Figure 11.19: Bayer R&D Expenditure by Geographical Region FY2012-FY2013 223
Figure 11.20: Mylan Pharmaceuticals Total Revenue FY2012-FY2013 224
Figure 11.21: Mylan Pharmaceuticals Consolidated Gross Profit FY2012-FY2013 225
Figure 11.22: Mylan Pharmaceuticals Global & Country Level Approvals & Submissions FY2013 225
Figure 11.23: Mylan Pharmaceuticals Number of Country Level Product Submissions 2013 226
Figure 11.24: Mylan Pharmaceuticals Country Level Product Approvals 2013, Globally 226
Figure 11.25: Mylan Pharmaceuticals R&D Spending 2011-Present 227
Figure 11.26: Mylan Pharmaceutical Percentage Consolidated Net Revenue Share of Major Customers, 2011-2013 227
Figure 11.27: Novartis Net Sales ($ Billions) FY2012-FY2013 228
Figure 11.28: Novartis Net Sales ($ Billions) by Geography, FY2013 229
Figure 11.29: Novartis Percentage Net Sales by Geography, FY2013 229
Figure 11.30: Novartis R&D Expenditure by Business Area FY2013 230
Figure 11.31: Novartis Exelon/Exelon Patch Net Sales by Geography FY2013 231
Figure 11.32: Novartis Pipeline Portfolio 2014-2018 and Beyond 232
Figure 11.33: Johnson & Johnson Total Sales by Business Division: Pharmaceuticals, Medical Devices & Diagnostics, Consumer Health FY2013 233
Figure 11.34: Johnson & Johnson Distribution of Sales – Pharmaceuticals, Medical Devices & Diagnostics, Consumer Health FY2013 234
Figure 11.35: Johnson & Johnson Pharmaceutical Segment Sales FY2013 234
Figure 11.36: Johnson & Johnson Medical Device and Diagnostic Sales FY2013 235
Figure 11.37: Johnson & Johnson Consumer Healthcare Sales FY2013 235
Figure 11.38: Shire Global Revenue and Sales FY2013 236
Figure 11.39: Shire Sales by Geography FY2013 236
Figure 11.40: Nitto Dento Sales Revenue (Yen, millions) FY2008-FY2013 237
Figure 11.41: Nitto Dento Net Income (Yen millions) FY2008-FY2013 238
Figure 11.42: Nitto Dento Geographical Breakdown of Sales FY2013 238
Figure 11.43: Teva Pharmaceuticals Global Gross Profit FY2006-FY2013 239
Figure 11.44: Teva Pharmaceuticals Global Net Income FY2006-FY2013 240
Figure 11.45: Endo International Revenue by Business Segment (US $ Millions) FY2013 243
Figure 11.46: Endo International Top Selling Product Revenue FY2013 244
Figure 11.47: Endo International Global Lidoderm Sales FY2011-FY2013 244
Figure 11.48: Endo International Global Fortesa Sales FY2011-FY2013 245
Figure 11.49: Boehringer Ingelheim Sales by Business Segment FY2013 246
Figure 11.50: Boehringer Ingelheim Sales by Geographic Region FY2013 247
Figure 11.51: 3M Net Sales by Geographical Region FY2013 249
Figure 11.52: 3M Research & Development Spend FY2011-FY2013 250
Figure 11.53: UCB Revenue & Earnings Before Tax (€ Millions) FY2009-FY2013 251
Figure 11.54: UCB Geographical Sales FY2013 252
Figure 11.55: UCB Key Product Sales FY2013 253
Figure 11.56: ParPharm Top Generic Products by Revenue FY2013 254
Figure 12.1 Niquitin Transdermal System Patch Technology 257
Global Gold Nanoparticles Market Research Report 2024
Published: 08-Jan-2024 Price: US 2900 Onwards Pages: 121
Gold nanoparticles are particles with diameters in The 1-100nm range and have unique optical and physical properties. These unique optical-electronics properties have been researched and utilized in high technology applications such as organic photovoltaics, sensory probes, therapeutic agents, drug delivery in biological and medical applications, electronic conductors and catalysis. The optical and electronic properties of gold nanoparticles are tunable by changing The size, shape, surface chemi......
Global High Volume Subcutaneous Drug Delivery Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 109
Market Overview of Global High Volume Subcutaneous Drug Delivery market:
According to our latest research, the global High Volume Subcutaneous Drug Delivery market looks promising in the next 5 years. As of 2022, the global High Volume Subcutaneous Drug Delivery market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a dee......
Global Gold Nanoparticles Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 134
According to our LPI (LP Information) latest study, the global Gold Nanoparticles market size was valued at US$ 86 million in 2023. With growing demand in downstream market, the Gold Nanoparticles is forecast to a readjusted size of US$ 200.8 million by 2030 with a CAGR of 12.9% during review period.
The research report highlights the growth potential of the global Gold Nanoparticles market. Gold Nanoparticles are expected to show stable growth in the future market. However, product diff......
Global Liposome Drug Delivery Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 123
According to our LPI (LP Information) latest study, the global Liposome Drug Delivery market size was valued at US$ 3652.8 million in 2023. With growing demand in downstream market, the Liposome Drug Delivery is forecast to a readjusted size of US$ 8742.8 million by 2030 with a CAGR of 13.3% during review period.
The research report highlights the growth potential of the global Liposome Drug Delivery market. Liposome Drug Delivery are expected to show stable growth in the future market. ......
Global Transdermal Drug Delivery System Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 127
According to our LPI (LP Information) latest study, the global Transdermal Drug Delivery System market size was valued at US$ 14730 million in 2023. With growing demand in downstream market, the Transdermal Drug Delivery System is forecast to a readjusted size of US$ 36410 million by 2030 with a CAGR of 13.8% during review period.
The research report highlights the growth potential of the global Transdermal Drug Delivery System market. Transdermal Drug Delivery System are expected to sho......
Global Liposomes Drug Delivery Market Growth 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 117
According to our LPI (LP Information) latest study, the global Liposomes Drug Delivery market size was valued at US$ 3262.7 million in 2023. With growing demand in downstream market, the Liposomes Drug Delivery is forecast to a readjusted size of US$ 6510.7 million by 2030 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Liposomes Drug Delivery market. Liposomes Drug Delivery are expected to show stable growth in the future mark......
Global Gold Nanoparticles Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
Published: 01-Jan-2024 Price: US 3480 Onwards Pages: 129
According to our (Global Info Research) latest study, the global Gold Nanoparticles market size was valued at USD 91 million in 2023 and is forecast to a readjusted size of USD 198.5 million by 2030 with a CAGR of 11.9% during review period.
Gold nanoparticles are particles with diameters in the 1-100nm range and have unique optical and physical properties. These unique optical-electronics properties have been researched and utilized in high technology applications such as organic photov......
Global Polymers Drug Delivery Market Research Report 2023, Forecast to 2028
Published: 27-Dec-2023 Price: US 2680 Onwards Pages: 160
Polymeric drug delivery system has defined as a formulation or a device that enables the introduction of a therapeutic substance into the body. It improves its safety and efficacy by controlling the rate, time, and place of release of drugs in the body.
Polymeric drug delivery system has defined as a formulation or a device that enables the introduction of a therapeutic substance into the body. It improves its safety and efficacy by controlling the rate, time, and place of release of drug......
Global Polymers Drug Delivery Professional Survey Report 2023, Forecast to 2028
Published: 27-Dec-2023 Price: US 3280 Onwards Pages: 135
Polymeric drug delivery system has defined as a formulation or a device that enables the introduction of a therapeutic substance into the body. It improves its safety and efficacy by controlling the rate, time, and place of release of drugs in the body.
Polymeric drug delivery system has defined as a formulation or a device that enables the introduction of a therapeutic substance into the body. It improves its safety and efficacy by controlling the rate, time, and place of release of drug......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
